Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTOPUS - ovarian cancer trials of weekly paclitaxel
ISRCTN16426935Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of vistusertib and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Progression-free survival. Started Dec 2015; status: completed.
02
Drugs
vistusertibpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ISRCTN16426935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16426935.